increased expectations for pricing ($80,000 in the U.S.) and market penetration (25% peak). The acquisition of InterMune closed at the end of September, and Esbriet received approval on Oct. 15 in the U.S. Diagnostics growth stands at 6
has announced that it plans to acquire InterMune for $74 per share, or $8.3 billion ..... which represents a 63% premium to InterMune 's $45 share price prior to the start ..... close this year, and we're raising our InterMune fair value estimate to match the offer
InterMune reported second-quarter results that were consistent with our expectations ..... materially affect our valuation. The current regulatory timeline for InterMune is a six-month Food and Drug Administration review, based on the drug
May 19 (Reuters) - InterMune Inc shares jumped as much as 15 percent on Monday, after the biotechnology company said it would resubmit for U.S. approval its drug to treat a fatal lung disease after...
results of Phase III clinical trials for InterMune ’s Esbriet and Boehringer Ingelheim ..... our no-moat, stable trend rating for InterMune . The general view from physicians was ..... The current regulatory timeline for InterMune is to resubmit its application to the
InterMune reported first-quarter results that were better than our expectations and increased its Esbriet guidance for the year. Nevertheless
BANGALORE (Reuters) - Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim's rival drug had mixed results in late-stage trials.
limited detail to directly compare with InterMune ’s Phase III results, the key takeaway ..... Overall, this does not change our view on InterMune ’s prospects as we were anticipating ..... our market model for Esbriet. While InterMune ’s stock is reacting positively to the
InterMune announced preliminary fourth-quarter ..... Overall, this is positive news for InterMune , and we are maintaining our $17 per share ..... potentially lucrative market. For 2013, InterMune ’s revenue was $70.2 million
per share fair value estimate for InterMune ITMN following the release of second ..... limited drug lineup has prevented InterMune from establishing an economic moat ..... S.--as the key driver for InterMune shares, and top-line results